Kenneth Bate, Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 63,519 shares at $266.91 ($16.0M) on 2024-04-01, disclosed to the SEC on 2024-04-03.
Scheduled sale ($16.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $255.62 | 6,698 | $1.7M | 10.7% |
| 2 | $255.62 | 6,698 | $1.7M | 10.7% |
| 3 | $256.49 | 7,411 | $1.9M | 11.8% |
| 4 | $256.49 | 7,411 | $1.9M | 11.8% |
| 5 | $257.33 | 2,790 | $718K | 4.5% |
| 6 | $257.33 | 2,790 |
| $718K |
| 4.5% |
| 7 | $258.24 | 2,104 | $543K | 3.4% |
| 8 | $258.24 | 2,104 | $543K | 3.4% |
| 9 | $259.13 | 200 | $52K | 0.3% |
| 10 | $262.18 | 841 | $220K | 1.4% |
| 11 | $262.18 | 841 | $220K | 1.4% |
| 12 | $263.08 | 143 | $38K | 0.2% |
| 13 | $264.73 | 116 | $31K | 0.2% |
| 14 | $265.36 | 700 | $186K | 1.2% |
| 15 | $266.91 | 274 | $73K | 0.5% |
| 16 | $266.91 | 274 | $73K | 0.5% |
| 17 | $243.28 | 1,217 | $296K | 1.8% |
| 18 | $243.28 | 1,217 | $296K | 1.8% |
| 19 | $244.27 | 7,048 | $1.7M | 10.7% |
| 20 | $244.27 | 7,048 | $1.7M | 10.7% |
| 21 | $244.97 | 2,080 | $510K | 3.2% |
| 22 | $244.97 | 2,080 | $510K | 3.2% |
| 23 | $246.20 | 567 | $140K | 0.9% |
| 24 | $246.20 | 567 | $140K | 0.9% |
| 25 | $246.88 | 100 | $25K | 0.2% |
| 26 | $248.49 | 193 | $48K | 0.3% |
| 27 | $249.05 | 7 | $2K | 0.0% |
| Total | $252.68 avg | 63,519 | $16.0M | 100% |
| Filing → |
| MDGL | SELL | 2025-02-28 | $14.0M | — | Filing → |
| CBST | SELL | 2014-02-04 | $451K | — | Filing → |
| CBST | SELL | 2014-01-09 | $700K | — | Filing → |